Active, not recruitingPhase 1NCT04047251
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma
Studying Cutaneous neuroendocrine carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Intervention
- FF-10850 Topotecan Liposome Injection(drug)
- Enrollment
- 96 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2026
Study locations (7)
- HonorHealth, Scottsdale, Arizona, United States
- Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
- Dana Farber Cancer Institute (DFCI), Boston, Massachusetts, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- Ohio State University Wexner Medical Center, Columbus, Ohio, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04047251 on ClinicalTrials.govOther trials for Cutaneous neuroendocrine carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07302347A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT07288073TIL Therapy in cSCC and MCCKaram Khaddour, MD, MS
- RECRUITINGNCT07215988Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational StudyOhio State University Comprehensive Cancer Center
- RECRUITINGPHASE2, PHASE3NCT06947928Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell CarcinomaTuHURA Biosciences, Inc.
- RECRUITINGPHASE1NCT06940440IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)TuHURA Biosciences, Inc.
- RECRUITINGNCT06780475Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell CarcinomaAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE1NCT07080242Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine TumorsSystImmune Inc.
- RECRUITINGNCT06608511Liquid Biomarker Study in Melanoma and Non-Melanoma Skin CancersUniversity of Wisconsin, Madison